CJC-1295

What is CJC-1295?

CJC-1295 is a synthetic analogue of GHRH(1–29), a shortened version of growth hormone-releasing hormone. GHRH is the natural signal from the hypothalamus that tells the pituitary to synthesise and release growth hormone. The analogue is designed to be more stable than the natural peptide and to degrade more slowly.

Two frequently mentioned versions exist: with DAC and without DAC. DAC (maleimidopropionic acid) enables binding to albumin in the blood, which prolongs the peptide’s presence in circulation. The version without DAC lacks this property, so its action profile is shorter and closer to a physiological pulse.

How does it work?

CJC-1295 binds to GHRH receptors in the pituitary. This increases the synthesis and release of growth hormone, which then acts on the liver and other tissues, partly via insulin-like growth factor 1 (IGF-1). This is an indirect pathway: the peptide does not contain the hormone and does not replace it.

Because of feedback loops, the response is complex. The amount of hormone released is not linearly dependent on the dose, but on the state of the pituitary, somatostatin and other factors.

What does the research show?

Pharmacokinetic studies show that the version with DAC remains in circulation substantially longer than the version without DAC. This matters when designing experiments: to study a physiological pulse, a shorter profile is more appropriate; for continuous exposure, a different approach is needed.

There are too few clinical studies demonstrating long-term benefit in humans, and too few data on possible adverse effects with long-term use. For researchers, this means measurable objectives and reproducible methods.

Common misconceptions

• “CJC-1295 is growth hormone.” It is not. It is a signal that stimulates the body’s own release.
• “A larger dose means a greater effect.” The endocrine system works with feedback loops; the relationship is not necessarily linear.
• “Without DAC it is weaker.” It is not weaker, only shorter. It is a different profile, not a matter of quality.
• “A research peptide is safe because it is natural.” Natural does not mean safe, especially not with injection or long-term use.

Safety and regulation

CJC-1295 is not an approved medicine in the EU. In competitive sport, GHRH analogues may be prohibited, so check the WADA list. Any adverse effects of increased growth hormone release must be taken seriously and managed under professional supervision.

Quality and storage

The batch is declared with a purity of ≥ 98 % (HPLC) and confirmed identity. Store the lyophilizate at −20 °C, protected from light and moisture. After reconstitution, follow the laboratory protocol and store at 2–8 °C.

Conclusion

CJC-1295 without DAC is a research tool for studying the GHRH axis and pulsatile growth hormone secretion. Its use requires a clear understanding of pharmacokinetics and of the limits of the evidence.